注射用紫杉醇(白蛋白结合型)与替吉奥联合对进展期胰腺癌疗效观察及安全性评价

The clinical efficacy of Paelitaxel(ABRAXANE)combined with Tegafur Gimeracil Oteracil in treatment of advanced pancreatic cancer and its safety evaluation

[目的]探讨注射用紫杉醇（白蛋白结合型）与替吉奥联合对进展期胰腺癌疗效及安全性评价。[方法]选自2013年4月~2015年4月期间我院收治的进展期胰腺癌患者68例,依据随机数字表法将68例患者随机分为观察组34例与对照组34例。对照组单用替吉奥胶囊治疗,观察组在对照组基础上注射用紫杉醇（白蛋白结合型）治疗。2组均以每21d为一个周期,连续用药3个周期评价疗效。比较2组患者治疗近期疗效,治疗前后血清CA19-9和CEA水平、QOL评分和Karnofsky评分变化及用药期间药物毒副反应发生情况。[结果]观察组RR率（64.71%）高于对照组（41.18%）（P〈0.05）;2组血清CA19-9和CEA水平治疗后明显下降（P〈0.05）;观察组血清CA19-9和CEA水平治疗后明低于对照组（P〈0.05）;2组QOL评分和Karnofsky评分治疗后明显增加（P〈0.05）;观察组QOL评分和Karnofsky评分治疗后明显高于对照组（P〈0.05）;2组毒副反应比较差异无统计学意义（P〉0.05）。[结论]注射用紫杉醇（白蛋白结合型）与替吉奥联合对进展期胰腺癌疗效明显,安全性良好,具有重要研究意义。

[Objective]To investigate the clinical efficacy of Paelitaxel（ABRAXANE）combined with Tegafur Gimeracil Oteracil in treatment of advanced pancreatic cancer and its safety evaluation.[Methods]68cases of patients with advanced pancreatic cancer from April 2013 to April 2015 were randomly divided into observation group（n=34）and control group（n=34）according to random number table.The control group were given Tegafur Gimeracil Oteracil Potassium Capsule alone,while the observation group were treated with injection of Paelitaxel on the basis of treatment in control group.Cycle that over 21 din both groups,and estimate the curative effect after 3cycles of continuous medication.To make a comparison of curative effect,the serum CA19-9and CEA levels,changes of QOL scores and Karnofsky scores in before and after treatments and the incidence of side effects in both groups.[Results]The RR rate in observation group（64.71%）were significantly higher than that of the control group（41.18%）（P0.05）;the serum CA19-9and CEA levels in both groups were significantly decreased after treatments（P0.05）;the serum CA19-9and CEA levels in observation group were significantly lower than that of the control group（P0.05）;the QOL scores and Karnofsky scores in both groups were significantly increased after treatments（P0.05）;the QOL scores and Karnofsky scores in observation group were significantly higher than that of the control group（P0.05）;side effects were no significant difference between both groups（P0.05）.[Conclusion]Paelitaxel（ABRAXANE）combined with Tegafur Gimeracil Oteracil in treatment of advancedpancreatic cancer brought a striking effects and better security with fatal research significance.